Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

@article{Mcclung2009EfficacyAS,
  title={Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.},
  author={Michael R Mcclung and Michael A. Bolognese and Farhad Sedarati and Robert R. Recker and Paul D. Miller},
  journal={Bone},
  year={2009},
  volume={44 3},
  pages={
          418-22
        }
}
INTRODUCTION Monthly oral ibandronate has been shown to increase bone mineral density (BMD) and reduce bone turnover in postmenopausal women with osteoporosis, but its efficacy has not been investigated in women with low bone mass. The objective of this study was to examine the efficacy and safety of monthly oral ibandronate (150 mg) treatment in postmenopausal women with low bone mass. METHODS This 1-year, double-blind, placebo-controlled, randomized study enrolled ambulatory postmenopausal… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.

  • Health technology assessment
  • 2016
VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2017